Table 1 Demographic and clinical characteristics of the study patients
From: Frequency and risk factors for rebleeding events in patients with small bowel angioectasia
Characteristics | Total | Endoscopic treatment (+) | Endoscopic treatment (-) | P value* |
|---|---|---|---|---|
Number | 68 | 22 | 46 | Â |
Bleeding pattern (overt/occult) | 40/28 | 19/3 | 21/25 | 0.002 |
Number of angioectasia, mean (median) | 3.4 (2.5) | 4.0 (2.0) | 3.1 (3.0) | 0.68 |
Age, year, mean ± SD | 67.6 ± 12.8 | 66.9 ± 10.9 | 66.5 ± 13.6 | 0.30 |
Sex, Male/Female | 38/30 | 11/11 | 27/19 | 0.60 |
Drinking history (%) | 23 (33.8) | 11 (50.0) | 12 (26.0) | 0.06 |
Smoking history (%) | 24 (35.3) | 7 (31.8) | 17 (37.0) | 0.79 |
Blood transfusion (%) | 31 (45.6) | 17 (77.3) | 14 (30.4) | 0.001 |
Minimum hemoglobin value, g/dl | 9.3 ± 2.7 | 8.0 ± 2.0 | 9.9 ± 2.9 | 0.006 |
Follow-up duration, month, median (IQR) | 30.5 (16.5-47.0) | 34.0 (21.0-46.5) | 30.0 (18.0-46.0) | 0.76 |
Rebleeding rate, number (%) | 23 (33.8) | 5 (22.7) | 18 (39.1) | 0.27 |
Iron replacement therapy after OGIB, number (%) | 59 (86.8) | 20 (91.0) | 39 (84.8) | 0.71 |
Comorbidity, number (%) | Â | Â | Â | Â |
Hypertension | 46 (67.6) | 19 (86.4) | 27 (58.7) | 0.03 |
Diabetes | 15 (22.1) | 7 (31.8) | 8 (17.4) | 0.22 |
Cardiovascular disease | 18 (26.5) | 8 (36.4) | 10 (21.7) | 0.25 |
Cerebral infarction | 9 (13.2) | 3 (13.6) | 6 (13.0) | >0.99 |
CKD, ≥ stage 4 | 17 (86.4) | 8 (36.4) | 9 (19.6) | 0.15 |
Liver cirrhosis | 3 (4.4) | 1 (4.5) | 2 (4.3) | >0.99 |
Medication used, number (%) | Â | Â | Â | Â |
Warfarin | 9 (13.2) | 4 (18.2) | 5 (10.9) | 0.46 |
LDA | 27 (39.7) | 10 (45.5) | 17 (37.0) | 0.60 |
Thienopyridine | 9 (13.2) | 3 (13.6) | 6 (13.0) | >0.99 |
NSAIDs | 7 (10.3) | 2 (9.1) | 5 (10.9) | >0.99 |
H2-blockers | 17 (25.0) | 5 (22.7) | 12 (26.1) | >0.99 |
PPIs | 25 (36.8) | 8 (36.4) | 17 (37.0) | >0.99 |
Rebamipide | 10 (14.7) | 4 (18.2) | 6 (13.0) | >0.99 |